These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9590373)

  • 1. Misleading serum free thyroxine results during low molecular weight heparin treatment.
    Stevenson HP; Archbold GP; Johnston P; Young IS; Sheridan B
    Clin Chem; 1998 May; 44(5):1002-7. PubMed ID: 9590373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extremely low doses of heparin release lipase activity into the plasma and can thereby cause artifactual elevations in the serum-free thyroxine concentration as measured by equilibrium dialysis.
    Jaume JC; Mendel CM; Frost PH; Greenspan FS; Laughton CW
    Thyroid; 1996 Apr; 6(2):79-83. PubMed ID: 8733876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of heparin on serum free thyroxine linked to post-heparin lipolytic activity.
    Bayer MF
    Clin Endocrinol (Oxf); 1983 Nov; 19(5):591-6. PubMed ID: 6640958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.
    Merli G; Spiro TE; Olsson CG; Abildgaard U; Davidson BL; Eldor A; Elias D; Grigg A; Musset D; Rodgers GM; Trowbridge AA; Yusen RD; Zawilska K;
    Ann Intern Med; 2001 Feb; 134(3):191-202. PubMed ID: 11177331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased concentrations of serum free fatty acids falsely increase serum thyroxine as determined by competitive protein-binding.
    Pannall PR; Swanepoel E; Bennett JM; Pauw FH
    Clin Chem; 1977 Jun; 23(6):990-3. PubMed ID: 870262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin?
    Henry TD; Satran D; Knox LL; Iacarella CL; Laxson DD; Antman EM
    Am Heart J; 2001 Oct; 142(4):590-3. PubMed ID: 11579347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events.
    Cohen M; Demers C; Gurfinkel EP; Turpie AG; Fromell GJ; Goodman S; Langer A; Califf RM; Fox KA; Premmereur J; Bigonzi F
    Am J Cardiol; 1998 Sep; 82(5B):19L-24L. PubMed ID: 9737476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No difference in bleeding risk between subcutaneous enoxaparin and heparin for thromboprophylaxis in end-stage renal disease.
    Chan KE; Thadhani RI; Maddux FW
    Kidney Int; 2013 Sep; 84(3):555-61. PubMed ID: 23677243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heparin-induced release of protein-bound solutes during hemodialysis is an in vitro artifact.
    De Smet R; Van Kaer J; Liebich H; Lesaffer G; Verstraete A; Dhondt A; Duym P; Lameire N; Vanholder R
    Clin Chem; 2001 May; 47(5):901-9. PubMed ID: 11325895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.
    Stellbrink C; Nixdorff U; Hofmann T; Lehmacher W; Daniel WG; Hanrath P; Geller C; Mügge A; Sehnert W; Schmidt-Lucke C; Schmidt-Lucke JA;
    Circulation; 2004 Mar; 109(8):997-1003. PubMed ID: 14967716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation of enoxaparin for anticoagulation in early cardioversion of persisting nonvalvular atrial fibrillation: a statutory health insurance perspective from Germany.
    Schädlich PK; Schmidt-Lucke C; Huppertz E; Lehmacher W; Nixdorff U; Stellbrink C; Brecht JG
    Am J Cardiovasc Drugs; 2007; 7(3):199-217. PubMed ID: 17610347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medications that distort in vitro tests of thyroid function, with particular reference to estimates of serum free thyroxine.
    Stockigt JR; Lim CF
    Best Pract Res Clin Endocrinol Metab; 2009 Dec; 23(6):753-67. PubMed ID: 19942151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor.
    Xiao Z; Théroux P
    Circulation; 1998 Jan; 97(3):251-6. PubMed ID: 9462526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-molecular-weight heparin and unfractionated heparin in prophylaxis against deep vein thrombosis in critically ill patients undergoing major surgery.
    De A; Roy P; Garg VK; Pandey NK
    Blood Coagul Fibrinolysis; 2010 Jan; 21(1):57-61. PubMed ID: 19844176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between increased concentrations of free thyroxine and unsaturated free fatty acids in non-thyroidal illnesses: role of albumin.
    Tikanoja SH; Joutti A; Liewendahl BK
    Clin Chim Acta; 1989 Jan; 179(1):33-43. PubMed ID: 2920440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill?
    Priglinger U; Delle Karth G; Geppert A; Joukhadar C; Graf S; Berger R; Hülsmann M; Spitzauer S; Pabinger I; Heinz G
    Crit Care Med; 2003 May; 31(5):1405-9. PubMed ID: 12771610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The low molecular weight heparin enoxaparin reduces infarct size in a rat model of temporary focal ischemia.
    Quartermain D; Li YS; Jonas S
    Cerebrovasc Dis; 2003; 16(4):346-55. PubMed ID: 13130175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of enoxaparin in prevention of deep venous thrombosis in hip and knee surgery--a comparison with the dihydroergotamine-heparin combination.
    Perhoniemi V; Vuorinen J; Myllynen P; Kivioja A; Lindevall K
    Ann Chir Gynaecol; 1996; 85(4):359-63. PubMed ID: 9014067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heparin resistance and increased platelet activation in coronary surgery patients treated with enoxaparin preoperatively.
    Pleym H; Videm V; Wahba A; Asberg A; Amundsen T; Bjella L; Dale O; Stenseth R
    Eur J Cardiothorac Surg; 2006 Jun; 29(6):933-40. PubMed ID: 16675258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose low-molecular weight heparin (enoxaparin) is effective as adjuvant treatment in active ulcerative colitis: an open trial.
    Dotan I; Hallak A; Arber N; Santo M; Alexandrowitz A; Knaani Y; Hershkoviz R; Brazowski E; Halpern Z
    Dig Dis Sci; 2001 Oct; 46(10):2239-44. PubMed ID: 11680603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.